The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Van Ess, Peter
MetadataShow full item record
CitationJ Clin Hypertens (Greenwich) 2012, 14 (9):580-7
AbstractBlockade of the renin-angiotensin-aldosterone system (RAAS) is an established method to lower blood pressure in patients with hypertension. Aldosterone, the end product of the RAAS cascade, acts by increasing salt reabsorption in the kidney and catecholamine release from the adrenal medulla. Currently available aldosterone inhibitors have the disadvantage of increasing circulating aldosterone and thus may lead to aldosterone breakthrough. Aldosterone synthase inhibition (ASI) is a novel approach to suppressing the RAAS. Due to homology between the enzymes responsible for aldosterone synthesis (CYP11B2) and cortisol synthesis (CYP11B1), the blockade of aldosterone synthesis may also suppress cortisol release. The authors evaluated the effect of the novel ASI LCI699 on the cortisol response to adrenocorticotropic hormone (ACTH) stimulation in patients with hypertension in order to find the maximally tolerated dose (MTD) in this patient population. Among the 63 patients evaluated, there was a dose- and time-dependent effect of LCI699 on both aldosterone and ACTH-stimulated cortisol. Based on exposure-response analysis, the MTD was estimated to be 1.30 mg once daily with a 90% prediction interval of 0.88 mg once daily to 1.81 mg once daily. No patients required intervention for adrenal insufficiency. LCI699 was well tolerated with no serious adverse events.
RightsArchived with thanks to Journal of clinical hypertension (Greenwich, Conn.)
- Aldosterone synthase inhibition in humans.
- Authors: Azizi M, Amar L, Menard J
- Issue date: 2013 Jan
- Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
- Authors: Karns AD, Bral JM, Hartman D, Peppard T, Schumacher C
- Issue date: 2013 Mar
- Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review.
- Authors: Wang HZ, Tian JB, Yang KH
- Issue date: 2015
- Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy.
- Authors: Schumacher CD, Steele RE, Brunner HR
- Issue date: 2013 Oct
- Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
- Authors: Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Ménard J
- Issue date: 2011 Nov 1